Effects of different anti-rheumatic treatments of arthritis on antibody response following pneumococcal vaccination using Prevenar

Dept of Rheumatology, Lund University Hospital, Lund, Sweden0 sites500 target enrollmentDecember 20, 2007

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: Patients with rheumatic diseases (rheumatoid arthritis and spondyloarthripaties) who are going to be vaccinated with Prevenar vaccine in order to study the serological responses to two pneumococcal serotypes and to study the impact of different treatment modalities on serological responses.
Sponsor: Dept of Rheumatology, Lund University Hospital, Lund, Sweden
Enrollment: 500
Status: Active, not recruiting
Last Updated: 14 years ago

No summary available.

Registry

who.int

Start Date

December 20, 2007

End Date

TBD

Last Updated

14 years ago

Study Type

Interventional clinical trial of medicinal product

Sex

All

Sponsor

Dept of Rheumatology, Lund University Hospital, Lund, Sweden

•All patients with chronic arthritis treated with biologic agents ( such as TNF\-blockers, IL\-1 blocker or those receiving anti\-CD20 treatment) at Dept of Rheumatology in Lund and followed up with structured clinical protocol are eligible for this study. Thus the following groups of patients are planned to be studied:
•RA patients on methotrexate and/or other DMARDs
•RA patients on anti\-TNF drugs as monotherapy
•RA patients on anti\-TNF \+MTX and/or other DMARDs
•Spondylarthropathy patients on anti\-TNF drugs as monotherapy
•Spondylarthropathy patients on anti\-TNF drugs \+MTX
•Spondylarthropathy patients on NSAIDs
•(There is a possibility to stratify for steroid use).
•Are the trial subjects under 18? no
•Number of subjects for this age range:

•age\<18 years, pregnancy, allergi against the active substance in the vaccine, treatment with bilogical agens for conditions other than rheumatoid arthritis (RA) or spondylarthrophaties, ongoing infection